leadf
logo-loader
viewImugene Ltd

Imugene receives approval for phase I clinical trial of new checkpoint immunotherapy candidate PD1-VAX

The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and has recommended to proceed to the next dose escalation due to safety and tolerability.

Imugene Ltd - Imugene receives approval for phase I clinical trial of new checkpoint immunotherapy candidate PD1-VAX
Primary goal of the trial is to determine safety and an optimal biological dose as a monotherapy.

Imugene Limited (ASX:IMU) (OTCMKTS:IUGNF) has received Cohort Review Committee (CRC) approval for the Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx and will proceed to the second dose cohort.

The CRC unanimously agreed that PD1-Vaxx is safe with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed after CRC review of all safety and tolerability data for the first 3 patients dosed with the lowest dose of PD1-Vaxx (10mcg) as monotherapy.

After the completion of the review meeting, the CRC advised Imugene to proceed with opening the second PD1-Vaxx Phase 1 cohort at the 50mcg mid-dose level.

“No observed toxicity”

Imugene MD & CEO Leslie Chong said “We are pleased with the results that we have seen so far with no observed toxicity.

“Everyone supporting the study who are involved in developing this important new cancer therapy is very encouraged by the progress to date.

“We look forward to continuing this study and reporting to the market of its progress.”

PD1-Vaxx as a monotherapy

Clinicians at study sites in Australia and USA will also determine if the administration of PD1-Vaxx as a monotherapy in patients who have progressed on standard of care immune checkpoint inhibitors will prolong survival, delay tumour progression, or reduce the tumour burden in patients with lung cancer.

Imugene’s PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.

Phase I multi-centre study

The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.

Medical investigators are testing three different doses of PD1-Vaxx.

The primary goal of the Phase 1 trial is to determine the safety and an optimal biological dose as a monotherapy (mOBD).

Efficacy, tolerability and immune response will also be measured. Determination of mOBD will be made by the Cohort Review Committee (CRC) and requires successive dosing within cohorts of at least 3 patients each.

Quick facts: Imugene Ltd

Price: 0.1 AUD

ASX:IMU
Market: ASX
Market Cap: $475.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong details dose escalation for its phase I clinical...

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong discusses with Proactive's Andrew Scott the news the phase one clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, will proceed to the second dose. She says the cohort review committee agreed the therapy to be safe...

on 21/1/21

2 min read